Recent developments in research
- Exploring aging and cancer growth
- Toward effective therapies for SCLC
- Creating a new approach to treatment
- Studying SETD2 in cancer cells
- LCRF announces research collaboration with Israel Cancer Research Fund
- Science Update | Winter 2025
- Accelerated approval for drug targeting NRG1
- LCRF announces 2024 scientific research grants
- Breath analysis for lung cancer diagnosis?
Recent FDA approvals
- New FDA approval for EGFR exon 19 and exon 21 L858R
- FDA approves alectinib for ALK+ NSCLC
- Recent FDA approval of combined therapy for initial treatment of EGFR-mutated NSCLC
- FDA approves repotrectinib for patients with advanced ROS-1 fusion non-small cell lung cancer
- FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC
- FDA approves Imjudo with Imfinzi and chemo